Clinical approach to infectious diarrheas.
D000900:Anti-Bacterial Agents / Q000009:adverse effects; D001210:Asia, Southeastern; D001285:Atropine / Q000009:adverse effects; D002641:Chicago; D002771:Cholera / Q000382:microbiology; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000209:etiology / Q000382:microbiology*; D004338:Drug Combinations; D004405:Dysentery, Bacillary / Q000188:drug therapy / Q000382:microbiology*; D004927:Escherichia coli Infections / Q000382:microbiology; D005243:Feces / Q000166:cytology; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007540:Isonipecotic Acids / Q000009:adverse effects; D007958:Leukocyte Count; D010093:Oxolinic Acid / Q000627:therapeutic use; D012475:Salmonella / Q000472:pathogenicity; D012480:Salmonella Infections / Q000382:microbiology; D012485:Salmonella typhi / Q000472:pathogenicity; D012760:Shigella / Q000472:pathogenicity; D014481:United States; D014734:Vibrio cholerae / Q000472:pathogenicity; D014774:Virulence
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D007540:Isonipecotic Acids; D001285:Atropine; D010093:Oxolinic Acid